Device Trial Radar · NCT04768322
LVAD Versus GDMT in Ambulatory Advanced Heart Failure Patients
Last checked: Nov 20, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
92
Planned (sponsor's estimate)
Start
Feb 24, 2021
Primary completion
Feb 2029
Study completion Feb 2029
Sponsor
- Lead sponsor
- Hospices Civils de LyonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 24, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Heart failure is a severe disease affecting approximately 1-2% of the adult population in developed countries and around 26 million people worldwide. Up to 10% of these patients are in advanced stage heart failure, which is defined by a significant morbimortality and considerable medical expenses. Despite advances in its medical management, advanced (or end stage) heart failure is characterized by refractoriness to conventional therapies including guideline-directed pharmacological and non-surgical device treatments. These patients remain severely symptomatic (NYHA IV) and have objective signs of congestion or low cardiac output. Left ventricular assist devices (LVADs) have been used in patients with heart failure with reduced ejection fraction for almost 20 years either as an alternative or a bridge to heart transplantation. LVADs improve heart failure symptoms and survival at the cost of increased rates of infection, stroke and bleeding. Despite the lack of evidence, LVAD implantation in ambulatory patients is not rare, with INTERMACS profiles ≥4 patients representing 15.7% of the overall population implanted between 2012 and 2016. The aim of this study is to investigate the efficacy and safety of left ventricular assist devices compared to traditional HF medical treatment alone in a population of ambulatory advanced heart failure patients. Secondary objectives are to better identify subgroups of patients that would benefit the most from the implantation of an LVAD as well as to assess the optimal timing of intervention.
Conditions
- End-stage Heart Failure
Interventions
HeartMate 3 TM Left Ventricular Assist SystemDevice
The HeartMate 3 TM Left Ventricular Assist System will be implanted within 21 days of randomization.
Guideline Directed Medical TherapyOther
Patients randomized in the control group will continue their guideline directed medical therapy which comprises the following stable combination at the maximal tolerated dose of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or Angiotensin receptor Neprilysin inhibitor and Mineralocorticoid Receptor Antagonists and Sodium-GLucose co-Transporter-2 (SGLT2) inhibitors if tolerated.
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause mortality rateTime frame: Through 24 months when the last subject completes 12 months of follow-up
- Number of urgent ECMO implantationTime frame: Through 24 months when the last subject completes 12 months of follow-up
- Number of urgent heart transplantationTime frame: Through 24 months when the last subject completes 12 months of follow-up
4 more outcomes with a free account
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
CHU Besançon
Besançon, France · Recruiting
Hôpital Pneumologique et Cardiovasculaire Louis Pradel
Bron, France · Recruiting
CHU Caen
Caen, France · Recruiting
5 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.